HOME >> BIOLOGY >> NEWS
Embryos that implant in uterus 'late' prove more likely to die in first weeks of pregnancy

Researchers at the National Institute of Environmental Health Sciences said today that fertilized human eggs that implant late are less likely to survive.

The road to birth is a perilous one. These same NIEHS scientists showed in 1988 (New England Journal of Medicine, 319, pp 189-94) that 25 percent of fertilized eggs fail to survive six weeks -- so early that most mothers did not know they had been pregnant. Only daily urine testing for shifting traces of a hormone called hCG confirmed these pregnancies and their loss. The 25 percent early loss, when added to the clinical miscarriages that occur later, means that at least one-third of all embryos fail.

Today, the researchers reported they have found that the lost fetuses tend to be those that implant late. (NEJM, June 10.) The implantation of the fertilized egg in the wall of the uterus is necessary for the nourishment and growth of the fetus. Surviving pregnancies implanted only about one day earlier, on average, than the non-survivors: 10.5 days v. 9.1 days from fertilization to implantation. But the day-by-day trend was clear. If a fertilized egg implanted by the ninth day, it had only a 13 percent chance of loss. The risk rose to 26 percent if the implantation was on the tenth day, 52 percent on the eleventh day, and 82 percent thereafter. All three implantations after day 12 ended in early loss. There was no association in the NIEHS study between late implantation and the clinical miscarriages that occurred later in pregnancy.

NIEHS' Allen J. Wilcox, M.D., Ph.D., Donna Baird, Ph.D., and Clarice R. Weinberg, Ph.D., said their study could not determine the mechanisms at work. They speculate that embryos that implant more slowly may be imperfect in some way. Thus, they said, "the uterus may be receptive to pregnancy only during a limited time-window, shutting out defective embryos that get there too late. This would spare a mother the physiologic burden of supp
'"/>

Contact: Bill Grigg
grigg@niehs.nih.gov
301-402-3378
NIH/National Institute of Environmental Health Sciences
10-Jun-1999


Page: 1 2

Related biology news :

1. First Dinosaur Embryo Skin Discovered -- Unhatched Embryos Are First Ever Found Of Giant-Plant Eating Dinosaurs
2. Who Needs Flowers? Transgenic Plants Sprout Embryos On Leaves
3. At Lifes Most Sensitive Stage, Embryos Cope With Stress
4. University of Pittsburgh medical center among first to implant heart assist device
5. Medical implants work better when you rough them up, study finds
6. DCI donor services begins distribution of tissue implants
7. Researchers model embryo implantation and tumour metastasis in fruit flies
8. Injectable tissue implant could repair ravages of breast cancer surgery
9. Improving bone implant technology
10. Researchers envision intelligent implants
11. Rutgers researchers test polymer reliability for medical implants

Post Your Comments:
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... 17, 2014   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, announced today its presentation at ... San Francisco, CA. ... Officer, will present on Monday, January 12, 2015, at ... be webcast live and may be accessed from the ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: